KERBER, R.; LORENZ, E.; DURAFFOUR, S.; SISSOKO, Daouda; RUDOLF, M.; JAEGER, A.; CISSE, S. D.; CAMARA, A. M.; MIRANDA, O.; CASTRO, C. M.; AKOI BORE, J.; RAYMOND KOUNDOUNO, F.; REPITS, J.; AFROUGH, B.; BECKER-ZIAJA, B.; HINZMANN, J.; MERTENS, M.; VITORIANO, I.; HUGH LOGUE, C.; BOTTCHER, J. P.; PALLASCH, E.; SACHSE, A.; BAH, A.; CABEZA-CABRERIZO, M.; NITZSCHE, K.; KUISMA, E.; MICHEL, J.; HOLM, T.; ZEKENG, E. G.; COWLEY, L. A.; GARCIA-DORIVAL, I.; HETZELT, N.; BAUM, J. H. J.; PORTMANN, J.; CARTER, L.; YENAMABERHAN, R. L.; CAMINO, A.; ENKIRCH, T.; SINGETHAN, K.; MEISEL, S.; MAZZARELLI, A.; KOSGEI, A.; KAFETZOPOULOU, L.; RICKETT, N. Y.; PATRONO, L. V.; GHEBREGHIORGHIS, L.; ARNOLD, U.; COLIN, Geraldine; JUCHET, Sylvain; LEVY-MARCHAL, Claire; KOLIE, J. S.; BEAVOGUI, A. H.; WURR, S.; BOCKHOLT, S.; KRUMKAMP, R.; MAY, J.; STOECKER, K.; FLEISCHMANN, E.; IPPOLITO, G.; CARROLL, M. W.; KOIVOGUI, L.; MAGASSOUBA, N.; KEITA, S.; GURRY, C.; DRURY, P.; DIALLO, B.; FORMENTY, P.; WOLFEL, R.; CARO, A. D.; GABRIEL, M.; ANGLARET, Xavier; MALVY, Denis; GUNTHER, S.

doi:10.1093/infdis/jiz078

Langue

Article de revue

Ce document a été publié dans

Journal of Infectious Diseases. 2019-06-19, vol. 220, n° 2, p. 195-202

Résumé en anglais

BACKGROUND: In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. Cycle threshold (Ct) in the Ebola virus RT-PCR and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to EVD patients on compassionate use basis. METHODS: To reduce biases in the raw field data, we carefully selected 163 of the 286 EVD patients for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry, favipiravir treatment, and outcome. RESULTS: The case fatality rate in favipiravir-treated patients was lower than in untreated patients (31/73 [42.5%] vs. 52/90 [57.8%], p = 0.053 in univariate analysis). In the multivariate regression analysis, higher Ct value and younger age were associated with survival (p <0.001), while favipiravir treatment showed no statistically significant effect (p = 0.11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (p = 0.015). The study also showed characteristic changes in blood chemistry in fatal cases vs. survivors. CONCLUSIONS: Consistent with the JIKI trial, this retrospective study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect was not statistically significant except for survival time.< Réduire

Mots clés en anglais

IDLIC

URI

https://oskar-bordeaux.fr/handle/20.500.12278/8187

DOI

http://dx.doi.org/10.1093/infdis/jiz078

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche